Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.52 |
| ▸ | BHMT | Q93088 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRE | P78334 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648478 | 1.00 | SLC7A5 (0.52) | SLC7A5BHMTTDP1GABRPGABRD | |
| SCHEMBL75174 | 1.00 | SLC7A5 (0.52) | SLC7A5BHMTTDP1GABRPGABRD | |
| SCHEMBL2263294 | 1.00 | SLC7A5 (0.52) | SLC7A5BHMTTDP1GABRPGABRD | |
| SCHEMBL497652 | 1.00 | SLC7A5 (0.52) | SLC7A5BHMTTDP1GABRPGABRD | |
| SCHEMBL7411924 | 0.84 | SLC7A5 (0.46) | SLC7A5BHMTTDP1GABRPGABRD | |
| SCHEMBL14689821 | 0.83 | ALDH1A1 (0.38) | SLC7A5BHMTGABRPGABRDGABRA1 | |
| SCHEMBL24261803 | 0.83 | BHMT (0.40) | SLC7A5BHMTTDP1GABRPGABRD | |
| SCHEMBL5319867 | 0.83 | SLC7A5 (0.50) | SLC7A5BHMTKMT2ASLC1A3SLC1A2 | |
| SCHEMBL5319869 | 0.83 | SLC7A5 (0.50) | SLC7A5BHMTKMT2ASLC1A3SLC1A2 | |
| SCHEMBL10824295 | 0.83 | SLC7A5 (0.50) | SLC7A5BHMTKMT2ASLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 516 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | claimed |
| US-20220026398-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2022-01-27 | — | — | US | claimed |
| CN-113301893-A | Treatment of neurological disorders | 阿克里普斯一有限公司 | 2021-08-24 | — | — | CN | claimed |
| CN-109298115-A | A variety of metabolin quantitative detecting methods and metabolism chip in biological sample | 深圳市绘云生物科技有限公司 | 2019-02-01 | — | — | CN | claimed |
| EP-3335720-A1 | C-DI-GMP BINDING PEPTIDES | Universität Basel (CH) | 2018-06-20 | — | — | EP | claimed |
| CN-104974055-B | The preparation method of the methyl glutamate derivatives of optical voidness 3 | 河北科技大学 | 2017-12-05 | — | — | CN | claimed |
| CN-104974055-A | Preparation method of optically pure 3-methyl glutamic acid derivative | UNIV HEBEI SCIENCE & TECH | 2015-10-14 | — | — | CN | claimed |
| CN-102485902-B | Method for producing daptomycin by fermentation | UNIV PEKING FOUNDER GROUP CO | 2014-08-13 | — | — | CN | claimed |
| CN-102485902-A | Method for producing daptomycin by fermentation | UNIV PEKING FOUNDER GROUP CO | 2012-06-06 | — | — | CN | claimed |
| WO-2002059322-A9 | COMPOSITIONS AND METHODS RELATING TO THE DAPTOMYCIN BIOSYNTHETIC GENE CLUSTER | CUBIST PHARMACEUTICLAS INC (US) | 2003-05-01 | — | — | WO | claimed |
| WO-2002059322-A2 | COMPOSITIONS AND METHODS RELATING TO THE DAPTOMYCIN BIOSYNTHETIC GENE CLUSTER | CUBIST PHARMACEUTICLAS, INC. (US) | 2002-08-01 | — | — | WO | claimed |
| US-6310093-B1 | ADMINISTERING, IN AMOUNT EFFECTIVE TO REDUCE DAMAGE TO NEURONAL CELLS, COMPOUND WHICH SELECTIVELY INHIBITS EXTRACELLULAR GLUTAMINASE RELATIVE TO GLUTAMINASE PRESENT IN INTACT CELLS AND IS IMPERMEABLE TO INTACT CELL MEMBRANES | ELAN PHARMACEUTICALS, INC. | 2001-10-30 | — | — | US | claimed |
| WO-1999009825-A1 | METHOD OF PREVENTING NEURONAL DEATH | ELAN PHARMACEUTICALS, INC. (US) | 1999-03-04 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| EP-0010421-B1 | MIXTURE OF ANTIBIOTICS DESIGNATED BY A-21978, PROCESS FOR ITS PRODUCTION, THEIR PHARMACEUTICAL COMPOSITIONS AND PRODUCING MICROORGANISM | ELI LILLY AND COMPANY (US) | 1990-10-10 | — | — | EP | claimed |
| US-RE32455-E | A-21978 antibiotics and process for their production | ELI LILLY AND COMPANY (US) | 1987-07-07 | — | — | US | claimed |
| US-4331594-A | PEPTIDE ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1982-05-25 | — | — | US | claimed |
| EP-0010421-A1 | Mixture of antibiotics designated by A-21978, process for its production, their pharmaceutical compositions and producing microorganism | ELI LILLY AND COMPANY (US) | 1980-04-30 | — | — | EP | claimed |
| JP-6273417-A | — | — | None | — | — | JP | disclosed |
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | disclosed |
| US-20250177537-A1 | AN ANTIBIOTIC, METHOD OF PREPARATION AND METHOD OF TREATMENT THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2025-06-05 | — | — | US | disclosed |
| CN-119823094-A | Heterocyclic tetrabasic acid, and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2025-04-15 | — | — | CN | disclosed |
| US-20250049815-A1 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | BUCK INST RES AGING (US) | 2025-02-13 | — | — | US | disclosed |
| US-20240325517-A1 | COMPOSITIONS AND METHODS TARGETING FILAMENTOUS BACTERIOPHAGE | INIMMUNE CORPORATION | 2024-10-03 | — | — | US | disclosed |
| CN-118697852-A | Pharmaceutical application of daptomycin derivative | 浙江工业大学 | 2024-09-27 | — | — | CN | disclosed |
| CN-111787939-B | Methods of treating CASTOR-related disorders | 圣朱德儿童研究医院有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118453594-A | Application of beta-carboline alkaloid in preparation of medicine for treating mitochondrial diseases | 温州医科大学 | 2024-08-09 | — | — | CN | disclosed |
| EP-4103160-B1 | NANOPARTICLES ENCAPSULATING SMALL MOLECULES | ETH ZUERICH (CH) | 2024-06-26 | — | — | EP | disclosed |
| EP-4380574-A2 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | Buck Institute for Research on Aging (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | disclosed |
| US-20230399688-A1 | COMPOSITIONS AND MULTIPLEXED SYSTEMS FOR COUPLED CELL-FREE TRANSCRIPTION-TRANSLATION AND PROTEIN SYNTHESIS AND METHODS FOR USING THEM | GENOMATICA INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4213943-A1 | COMPOSITIONS AND METHODS TARGETING FILAMENTOUS BACTERIOPHAGE | The University Of Montana (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-116249523-A | Alverine or derivatives thereof for the treatment of mitochondrial diseases or disorders associated with mitochondrial complex I deficiencies | 法国抗肌病协会 | 2023-06-09 | — | — | CN | disclosed |
| US-11667674-B2 | Antibacterial cyclic lipopeptides | VERSITECH LIMITED (CN) | 2023-06-06 | — | — | US | disclosed |
| CN-116041441-A | Synthesis method of daptomycin | 申联生物医药（上海）股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230080270-A1 | NANOPARTICLES ENCAPSULATING SMALL MOLECULES | ETH ZURICH (CH) | 2023-03-16 | — | — | US | disclosed |
| WO-2023014718-A2 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2023-02-09 | — | — | WO | disclosed |
| US-11572477-B2 | Prevention of biofilm formation | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| EP-4103160-A1 | NANOPARTICLES ENCAPSULATING SMALL MOLECULES | ETH Zurich (CH) | 2022-12-21 | — | — | EP | disclosed |
| CN-115379831-A | Nanoparticles encapsulating small molecules | 苏黎世联邦理工学院 | 2022-11-22 | — | — | CN | disclosed |
| CN-109476704-B | Antibacterial cyclic lipopeptides | 港大科桥有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20220241316-A1 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR, IS A NOVEL SENOLYTIC | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2022-08-04 | — | — | US | disclosed |
| CN-114599389-A | Variant FC domains and uses thereof | 奇达拉治疗公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2022060905-A1 | COMPOSITIONS AND METHODS TARGETING FILAMENTOUS BACTERIOPHAGE | THE UNIVERSITY OF MONTANA (US) | 2022-03-24 | — | — | WO | disclosed |
| EP-3955916-A1 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR, IS A NOVEL SENOLYTIC | Buck Institute for Research on Aging (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220026398-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| CN-113301893-A | Treatment of neurological disorders | 阿克里普斯一有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210254158-A1 | METHOD FOR PREDICTING A SUBJECTS RESPONSE TO SLC MODULATOR THERAPY | RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. | 2021-08-19 | — | — | US | disclosed |
| WO-2021160873-A1 | NANOPARTICLES ENCAPSULATING SMALL MOLECULES | ETH ZURICH (CH) | 2021-08-19 | — | — | WO | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10647746-B2 | Antibacterial cyclic lipopeptides | VERSITECH LIMITED (HK) | 2020-05-12 | — | — | US | disclosed |
| US-20200071543-A1 | PREVENTION OF BIOFILM FORMATION | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2020-03-05 | — | — | US | disclosed |
| US-20190345190-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10377699-B2 | Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue | THE UNIVERSITY OF HONG KONG (CN) | 2019-08-13 | — | — | US | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| CN-109476704-A | ANTIBACTERIAL CYCLIC LIPOPEPTIDES | 港大科桥有限公司 | 2019-03-15 | — | — | CN | disclosed |
| WO-2019046303-A1 | A METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-109298115-A | A variety of metabolin quantitative detecting methods and metabolism chip in biological sample | 深圳市绘云生物科技有限公司 | 2019-02-01 | — | — | CN | disclosed |
| US-20180237847-A1 | COMPOSITIONS AND MULTIPLEXED SYSTEMS FOR COUPLED CELL-FREE TRANSCRIPTION-TRANSLATION AND PROTEIN SYNTHESIS AND METHODS FOR USING THEM | AGAIN BIO APS (DK) | 2018-08-23 | — | — | US | disclosed |
| EP-3337490-A1 | COMPOSITIONS AND MULTIPLEXED SYSTEMS FOR COUPLED CELL-FREE TRANSCRIPTION-TRANSLATION AND PROTEIN SYNTHESIS AND METHODS FOR USING THEM | Genomatica, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-3335720-A1 | C-DI-GMP BINDING PEPTIDES | Universität Basel (CH) | 2018-06-20 | — | — | EP | disclosed |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| CN-104974055-B | The preparation method of the methyl glutamate derivatives of optical voidness 3 | 河北科技大学 | 2017-12-05 | — | — | CN | disclosed |
| EP-2699242-B1 | CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF | ALFAMA INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170291923-A1 | ANTIBACTERIAL CYCLIC LIPOPEPTIDES | VERSITECH LIMITED (HK) | 2017-10-12 | — | — | US | disclosed |
| WO-2017173932-A1 | ANTIBACTERIAL CYCLIC LIPOPEPTIDES | VERSITECH LIMITED (CN) | 2017-10-12 | — | — | WO | disclosed |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9629789-B2 | Rosacea treatments using polymetal complexes | OBAGI MEDICAL PRODUCTS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20170088576-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9593138-B2 | Nitrile-containing enzyme inhibitors and ruthenium complexes thereof | WAYNE STATE UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9579332-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| WO-2017031399-A1 | COMPOSITIONS AND MULTIPLEXED SYSTEMS FOR COUPLED CELL-FREE TRANSCRIPTION-TRANSLATION AND PROTEIN SYNTHESIS AND METHODS FOR USING THEM | GENOMATICA, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-9556113-B2 | Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment | THE SOUTH DAKOTA BOARD OF REGENTS (US) | 2017-01-31 | — | — | US | disclosed |
| US-9457035-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9428458-B2 | Substituted pyridoxine-lactam carboxylate-salts | ALCOBRA LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-9427397-B2 | Rosacea treatments and kits for performing them | OBAGI MEDICAL PRODUCTS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| EP-1816116-B3 | Chemical compositions and methods of making them | OMP INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20160184354-A1 | ROSACEA TREATMENTS AND KITS FOR PERFORMING THEM | JR CHEM, LLC (US) | 2016-06-30 | — | — | US | disclosed |
| CN-103772231-B | Compounds, its synthetic method and therepic use | GILEAD SCIENCES INC. (US) | 2016-02-03 | — | — | CN | disclosed |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150315131-A1 | COMBINATION USES OF DICHLOROACETATE AND OXAMATE, AND THEIR PRODRUGS, FOR CANCER TREATMENT | SANFORD RESEARCH | 2015-11-05 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| CN-104974055-A | Preparation method of optically pure 3-methyl glutamic acid derivative | UNIV HEBEI SCIENCE & TECH | 2015-10-14 | — | — | CN | disclosed |
| CN-104974055-A | Preparation method of optically pure 3-methyl glutamic acid derivative | UNIV HEBEI SCIENCE & TECH | 2015-10-14 | — | — | CN | disclosed |
| CN-104974055-A | Preparation method of optically pure 3-methyl glutamic acid derivative | UNIV HEBEI SCIENCE & TECH | 2015-10-14 | — | — | CN | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| CN-104774834-A | Method for screening daptomycin high-producing strain by adopting sodium glutamate tolerance model | SICHUAN IND INST ANTIBIOTICS CHINA NAT PHARMACEUTICAL GROUP CORP | 2015-07-15 | — | — | CN | disclosed |
| US-20150126707-A1 | DAPTOMYCIN ANALOGUES AND A METHOD FOR THE PREPARATION OF DAPTOMYCIN OR A DAPTOMYCIN ANALOGUE | THE UNIVERSITY OF HONG KONG (CN) | 2015-05-07 | — | — | US | disclosed |
| US-8952057-B2 | Compositions for anorectal use and methods for treating anorectal disorders | JR CHEM, LLC (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150025111-A1 | SUBSTITUTED PYRIDOXINE-LACTAM CARBOXYLATE-SALTS | ALCOBRA LTD. (IL) | 2015-01-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8889715-B2 | Substituted pyridoxine-lactam carboxylate salts | ALCOBRA LTD. (IL) | 2014-11-18 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140288294-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140272066-A1 | GLUTAMIC ACID DERIVATIVES | GIVAUDAN SA (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140248221-A1 | COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140228744-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC (US) | 2014-08-14 | — | — | US | disclosed |
| CN-102485902-B | Method for producing daptomycin by fermentation | UNIV PEKING FOUNDER GROUP CO | 2014-08-13 | — | — | CN | disclosed |
| US-20140134119-A1 | ROSACEA TREATMENTS USING POLYMETAL COMPLEXES | LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT (CA) | 2014-05-15 | — | — | US | disclosed |
| EP-2718299-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR Chem, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8697861-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20140100173-A1 | Nitrile-containing enzyme inhibitors and ruthenium complexes thereof | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-04-10 | — | — | US | disclosed |
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-1807118-B1 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HARBOR BIOSCIENCES INC (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-1907403-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| EP-1816116-B1 | Chemical compositions and methods of making them | JR CHEMICALS (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8505730-B2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | JR CHEM, LLC (US) | 2013-08-13 | — | — | US | disclosed |
| CN-102093186-B | Process for the preparation of an optically active compound | FIRMENICH & CIE | 2013-07-17 | — | — | CN | disclosed |
| US-20130090299-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130059887-A1 | SUBSTITUTED PYRIDOXINE-LACTAM CARBOXYLATE SALTS | ALCOBRA LTD. (IL) | 2013-03-07 | — | — | US | disclosed |
| CN-102952033-A | Novel compound, composing method thereof and therapeutic use therefor | GILEAD SCIENCES INC (US) | 2013-03-06 | — | — | CN | disclosed |
| CN-101223122-B | Substituted cyclohexanones | FIRMENICH & CIE | 2013-02-27 | — | — | CN | disclosed |
| US-20130039869-A1 | ROSACEA TREATMENTS AND KITS FOR PERFORMING THEM | JR CHEM, LLC (US) | 2013-02-14 | — | — | US | disclosed |
| CN-101243096-B | Antiviral compounds | GILEAD SCIENCES INC | 2013-02-06 | — | — | CN | disclosed |
| US-8367646-B2 | Steroid compounds and treatment methods | Harbor Therapeutics, Inc. (US) | 2013-02-05 | — | — | US | disclosed |
| WO-2012174076-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20120315223-A1 | COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC | 2012-12-13 | — | — | US | disclosed |
| US-20120315224-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC | 2012-12-13 | — | — | US | disclosed |
| US-20120312717-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | JR CHEM, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-8329926-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8318701-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| CN-101172957-B | Novel compound, synthetic method thereof and therapeutic usage | GILEAD SCIENCES INC (US) | 2012-11-14 | — | — | CN | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120258998-A1 | Fusion genes in gastrointestinal cancer | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2012-10-11 | — | — | US | disclosed |
| US-8273791-B2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | JR CHEM, LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2012096839-A1 | COMPOSITIONS FOR ANORECTAL USE AND METHODS FOR TREATING ANORECTAL DISORDERS | JR CHEM, LLC (US) | 2012-07-19 | — | — | WO | disclosed |
| CN-101914124-B | Nucleoside phosphonate conjugates as anti HIV agents | GILEAD SCIENCES INC | 2012-07-18 | — | — | CN | disclosed |
| US-20120177583-A1 | COMPOSITIONS FOR ANORECTAL USE AND METHODS FOR TREATING ANORECTAL DISORDERS | JR CHEM, LLC | 2012-07-12 | — | — | US | disclosed |
| US-20120177582-A1 | COMPOSITIONS FOR ANORECTAL USE AND METHODS FOR TREATING ANORECTAL DISORDERS | JR CHEM, LLC | 2012-07-12 | — | — | US | disclosed |
| CN-102532198-A | Antiviral phosphinate compounds | GILEAD SCIENCES INC | 2012-07-04 | — | — | CN | disclosed |
| CN-102485902-A | Method for producing daptomycin by fermentation | UNIV PEKING FOUNDER GROUP CO | 2012-06-06 | — | — | CN | disclosed |
| US-20120116027-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | BIOVIE INC. | 2012-04-26 | — | — | US | disclosed |
| EP-2043658-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-04-25 | — | — | EP | disclosed |
| CN-1780643-B | Antiviral phosphonate analogs | GILEAD SCIENCES INC | 2012-04-25 | — | — | CN | disclosed |
| US-20120071454-A1 | Steroid Compounds and Treatment Methods | HARBOR BIOSCIENCES, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | BIOVIE INC. | 2012-02-16 | — | — | US | disclosed |
| US-8106036-B2 | Pharmaceutical compositions-4 | HARBOR BIOSCIENCES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | NOVO NORDISK A/S (DK) | 2011-12-29 | — | — | US | disclosed |
| US-8076316-B2 | Steroid compounds and formulations | HARBOR BIOSCIENCES, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110294859-A1 | SUBSTITUTED PYRIDOXINE-LACTAM CARBOXYLATE SALTS | ALCOBRA LTD. (IL) | 2011-12-01 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| CN-102216325-A | Method for purifying human growth hormone polypeptides using affinity resins comprising specific ligands | NOVO NORDISK AS | 2011-10-12 | — | — | CN | disclosed |
| CN-102216319-A | Antibody purification method using affinity resin comprising specific ligand | NOVO NORDISK AS | 2011-10-12 | — | — | CN | disclosed |
| US-8022234-B2 | Compounds and compositions | HARBOR BIOSCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | FRINCKE JAMES M | 2011-09-08 | — | — | US | disclosed |
| EP-2356141-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | Novo Nordisk A/S (DK) | 2011-08-17 | — | — | EP | disclosed |
| EP-2346892-A1 | PROCESS FOR THE PURIFICATION OF ANTIBODIES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | Novo Nordisk A/S (DK) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178318-A1 | METHODS OF MAKING BIMETAL COMPLEXES | RAMIREZ JOSE E | 2011-07-21 | — | — | US | disclosed |
| US-20110144177-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | COLUCID PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| CN-102093186-A | Process for the preparation of an optically active compound | FIRMENICH & CIE | 2011-06-15 | — | — | CN | disclosed |
| US-7947846-B2 | 15-OXA-steroid compounds | HARBOR BIOSCIENCES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2322182-A1 | Androstenol derivatives as androgen receptor modulator | Harbor BioSciences, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7935839-B2 | Sepsis treatment methods | HARBOR BIOSCIENCES, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20110098260-A1 | Steroid Compounds and Formulations | HARBOR BIOSCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2314571-A2 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | CoLucid Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | BOOJAMRA CONSTANTINE G | 2011-03-24 | — | — | US | disclosed |
| US-7910571-B2 | 3 beta -hydroxy-16 alpha -fluoro-17 beta -aminoandrost-5-ene; immunostimulant, antiinflammatory agent; neutropenia, infections, blood cell deficiencies; interleukin, tumor necrosis factor, macrophage inflammatory protein, transforming growth factor, cyclooxygenase, and lipoxygenase inhibitor | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7906497-B2 | Cancer treatment methods | HARBOR BIOSCIENCES, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7897639-B2 | Amine group that, upon hydrolysis, becomes a component of a pharmacologically active agent for treatment of nervous system disordres | COLUCID PHARMACEUTICALS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897800-B2 | Chemical compositions and methods of making them | JR CHEM, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7871991-B2 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | GILEAD SCIENCES, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20110009372-A1 | Compounds and compositions | BIOVIE INC. | 2011-01-13 | — | — | US | disclosed |
| US-20110008271-A1 | ROSACEA TREATMENTS USING POLYMETAL COMPLEXES | JR CHEM, LLC (US) | 2011-01-13 | — | — | US | disclosed |
| CN-101935333-A | Nucleoside phosphonate conjugates as anti-hiv agent | GILEAD SCIENCES INC | 2011-01-05 | — | — | CN | disclosed |
| US-7863261-B2 | Breast and prostate cancer treatment method | HARBOR BIOSCIENCES, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| CN-101914124-A | Nucleoside phosphonate conjugates as anti-hiv agent | GILEAD SCIENCES INC | 2010-12-15 | — | — | CN | disclosed |
| US-7842672-B2 | Phosphonate inhibitors of HCV | GILEAD SCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| EP-0719273-B1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100240633-A1 | Cancer treatment methods | HARBOR BIOSCIENCES, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| CN-101031306-B | Nucleoside phosphonate conjugates as anti-HIV agents | GILEAD SCIENCES INC | 2010-09-22 | — | — | CN | disclosed |
| US-7795307-B2 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | COLUCID PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-7776845-B2 | Pharmaceutical compositions | HARBOR BIOSCIENCES, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| WO-2010085753-A1 | ROSACEA TREATMENTS AND KITS FOR PERFORMING THEM | JR CHEM, LLC (US) | 2010-07-29 | — | — | WO | disclosed |
| US-7723532-B2 | Pharmaceutical compositions 3 | HARBOR BIOSCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2010055135-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055136-A1 | PROCESS FOR THE PURIFICATION OF ANTIBODIES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| CN-101696235-A | Daptomycin analog and full solid phase synthesis preparation method thereof | UNIV NORTHWESTERN POLYTECHNIC | 2010-04-21 | — | — | CN | disclosed |
| US-7696189-B1 | Prostate and breast cancer treatment | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7691835-B2 | Formulations | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2166018-A2 | Antibody binding affinity ligands | Novo Nordisk A/S (DK) | 2010-03-24 | — | — | EP | disclosed |
| EP-1831243-B1 | ANTIBODY BINDING AFFINITY LIGANDS | NOVO NORDISK AS (DK) | 2010-03-17 | — | — | EP | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7642339-B2 | Hepatitis C; 1-benzyloxycarbonylamino-2-vinyl-cyclopropyl)-phenyl-phosphinic acid ethyl ester | GILEAD SCIENCES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-2125709-A2 | COMPOUNDS THAT INHIBIT CHOLINESTERASE | Colucid Pharmaceuticals, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| CN-101591281-A | Phosphonate compounds having immunomodulatory activity | GILEAD SCIENCES INC (US) | 2009-12-02 | — | — | CN | disclosed |
| EP-1910261-B1 | SUBSTITUTED CYCLOHEXANONES | FIRMENICH & CIE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | CANNIZZARO CARINA | 2009-09-10 | — | — | US | disclosed |
| US-20090215737-A1 | Pharmaceutical Compositions - 2 | BIOVIE INC. | 2009-08-27 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090202470-A1 | Phosphonate Analogs of Hiv Inhibitor Compounds | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| EP-2087880-A2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | Jr Chem, LLC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| CN-101489564-A | Antiviral phosphinate compounds | GILEAD SCIENCES INC (US) | 2009-07-22 | — | — | CN | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-20090176876-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | JR CHEM, LLC (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090156558-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | FARDIS MARIA | 2009-06-18 | — | — | US | disclosed |
| US-7547687-B2 | Therapeutic treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20090149648-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-7524835-B2 | Tetrol steroids and esters | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| CN-101410120-A | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES INC (US) | 2009-04-15 | — | — | CN | disclosed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| CN-101381379-A | Kinase inhibitor phosphonate conjugates | GILEAD SCIENCES INC (US) | 2009-03-11 | — | — | CN | disclosed |
| EP-2029111-A2 | MICROPARTICLES AND METHODS FOR PRODUCTION THEREOF | Baxter International Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008005565-A9 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-01-29 | — | — | WO | disclosed |
| US-7482334-B2 | Therapeutic treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20090012037-A1 | Antiviral Compounds | GILEAD SCIENCE, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-7470820-B2 | Substituted cyclohexanones | FIRMENICH SA (CH) | 2008-12-30 | — | — | US | disclosed |
| US-7470724-B2 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7462608-B2 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7439350-B2 | Nucleotide analogs | GILEAD SCIENCES, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432273-B2 | Phosphonate analogs of antimetabolites | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7427636-B2 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427624-B2 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080228008-A1 | Substituted Cyclohexanones | FIRMENICH SA (CH) | 2008-09-18 | — | — | US | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008097546-A2 | COMPOUNDS THAT INHIBIT CHOLINESTERASE | COLUCID PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-1955700-A2 | Therapeutic treatment of androgen receptor driven conditions | Hollis-Eden Pharmaceuticals Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| CN-101243096-A | Antiviral compounds | GILEAD SCIENCES INC (US) | 2008-08-13 | — | — | CN | disclosed |
| CN-100409844-C | neuraminidase inhibitors | GILEAD SCIENCES INC (US) | 2008-08-13 | — | — | CN | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080176824-A1 | Pharmaceutical Compositions 3 | BIOVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176823-A1 | Breast and Prostate Cancer Treatment Method | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080171724-A1 | Phosphonate Derivatives of Mycophenolic Acid | GILEAD SCIENCES, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| CN-101223122-A | Substituted cyclohexanones | FIRMENICH & CIE (CH) | 2008-07-16 | — | — | CN | disclosed |
| US-20080167270-A1 | ANTI-INFECTIVE PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2008-07-10 | — | — | US | disclosed |
| US-7396827-B2 | Pharmaceutical compositions and treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| CN-101189253-A | Antiinfective lipopeptides | CUBIST PHARM INC (US) | 2008-05-28 | — | — | CN | disclosed |
| US-20080107628-A1 | Polymerase inhibitors | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| CN-101172957-A | Selective inhibitors of viral or bacterial neuraminidase | GILEAD SCIENCES INC (US) | 2008-05-07 | — | — | CN | disclosed |
| US-20080090791-A1 | Cystic fibrosis treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| EP-1910261-A1 | SUBSTITUTED CYCLOHEXANONES | Firmenich SA (CH) | 2008-04-16 | — | — | EP | disclosed |
| US-20080085873-A1 | Disease treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| EP-1907403-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1906971-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1904506-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080076740-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| CN-101143859-A | Novel compound, its synthesis method and therapeutical uses | GILEAD SCIENCES INC (US) | 2008-03-19 | — | — | CN | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058301-A1 | Formulations | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045490-A1 | Pharmaceutical Compositions | BIOVIE INC. | 2008-02-21 | — | — | US | disclosed |
| CN-101124238-A | Antibody binding affinity ligands | NOVO NORDISK AS (DK) | 2008-02-13 | — | — | CN | disclosed |
| US-20080021006-A1 | Pharmaceutical Compositions | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| EP-1879657-A2 | USE OF COMPOUNDS TO ENHANCE PROCESSIVITY OF TELOMERASE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2008-01-23 | — | — | EP | disclosed |
| US-20080015174-A1 | Metabolic Disease Treatments | BIOVIE INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007147599-A1 | OPHTHALMOLOGICAL COMPOSITION AND USE THEREOF | ACRI.TEC AG GESELLSCHAFT FÜR OPHTALMOTOLOGISCHE PRODUCTE (DE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007143381-A2 | MICROPARTICLES AND METHODS FOR PRODUCTION THEREOF | BAXTER INTERNATIONAL INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281031-A1 | Microparticles and methods for production thereof | BAXTER HEALTHCARE S.A. (CH) | 2007-12-06 | — | — | US | disclosed |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | GILEAD SCIENCES, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070275959-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | SENTION, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275938-A1 | Therapeutic Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275937-A1 | Therapeutic Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-7300924-B2 | Anti-infective phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| CN-101074242-A | Cells accumulation for sphosphonate analogs of HIV protease inhibitor compound and the same compound | GILEAD SCIENCES INC (US) | 2007-11-21 | — | — | CN | disclosed |
| US-20070265236-A1 | Asthma Treatment Methods | BIOVIE INC. | 2007-11-15 | — | — | US | disclosed |
| EP-1509537-B9 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES INC (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| CN-101041669-A | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES INC (US) | 2007-09-26 | — | — | CN | disclosed |
| CN-100338031-C | Compounds and methods for synthesis and therapy | GILEAD SCIENCES INC (US) | 2007-09-19 | — | — | CN | disclosed |
| US-20070213309-A1 | Sepsis Treatment Methods | BIOVIE INC. | 2007-09-13 | — | — | US | disclosed |
| EP-1832598-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1831243-A2 | ANTIBODY BINDING AFFINITY LIGANDS | Novo Nordisk A/S (DK) | 2007-09-12 | — | — | EP | disclosed |
| CN-101031306-A | Nucleoside phosphonate conjugates as anti-HIV agents | GILEAD SCIENCES INC (US) | 2007-09-05 | — | — | CN | disclosed |
| US-20070203107-A1 | Pharmaceutical compositions | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203354-A1 | Chemical Compositions and Methods of Making Them | LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-30 | — | — | US | disclosed |
| CN-101027312-A | Antiviral compounds | GILEAD SCIENCES INC (US) | 2007-08-29 | — | — | CN | disclosed |
| CN-101027062-A | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES INC (US) | 2007-08-29 | — | — | CN | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1814588-A2 | ANTIINFECTIVE LIPOPEPTIDES | Cubist Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1816116-A1 | Chemical compositions and methods of making them | JR Chemicals (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2007084157-A2 | NUCLEOSIDE PRODRUGS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1809277-A2 | PHOSPHONATE DERIVATIVES OF MYCOPHENOLIC ACID | GILEAD SCIENCES, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1809299-A2 | PHOSPHONATE SUBSTITUTED KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1509537-B1 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1807118-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-7235651-B2 | Genes and proteins involved in the biosynthesis of lipopeptides | CUBIST PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | BIOVIE INC. | 2007-06-07 | — | — | US | disclosed |
| EP-1778249-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1778251-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| CN-1313472-C | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2007-05-02 | — | — | CN | disclosed |
| EP-1539183-A4 | THERAPEUTIC TREATMENT METHODS | HOLLIS EDEN PHARMACEUTICALS (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20070078081-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070072809-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2007-03-29 | — | — | US | disclosed |
| CN-1933844-A | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES INC (US) | 2007-03-21 | — | — | CN | disclosed |
| WO-2006110157-A9 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES INC (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049754-A1 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | GILEAD SCIENCES, INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1575486-A4 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2007014352-A2 | ANTIVIRAL PHOSPHONATE CONJUGATES FOR INHIBITION OF HIV | GILEAD SCIENCES, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070027114-A1 | Phosphonate analogs of antimetabolites | GILEAD SCIENCES INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027116-A1 | Therapeutic phosphonate derivatives | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2007010483-A1 | SUBSTITUTED CYCLOHEXANONES | FIRMENICH SA (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011658-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009109-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | BIOVIE INC. | 2007-01-18 | — | — | US | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2007002469-A2 | THERAPEUTIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002594-A1 | COSMETIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293228-A1 | Therapeutic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-20060293227-A1 | Cosmetic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
| EP-1715871-A1 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006114065-A2 | USE OF COMPOUNDS TO INHIBIT NEOPLASIA | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY A CADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006114064-A2 | USE OF COMPOUNDS TO ENHANCE PROCESSIVITY OF TELOMERASE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OFTHE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006110185-A2 | ANTIINFECTIVE LIPOPEPTIDES | CUBIST PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110172-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS.INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110157-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1711617-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2006102594-A1 | NUCLEOSIDE PRODRUGS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| CN-1837231-A | Immunomodulatory steroids, in particular the hemihydrate of 16, alpha-bromoepiandrosterone | HOLLIS EDEN PHARMACEUTICALS (US) | 2006-09-27 | — | — | CN | disclosed |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1689704-A2 | CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS | CoLucid Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| CN-1819832-A | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES INC (US) | 2006-08-16 | — | — | CN | disclosed |
| EP-1680129-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS AS PHOSPHONATE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006066598-A2 | ANTIBODY BINDING AFFINITY LIGANDS | NOVO NORDISK A/S (DK) | 2006-06-29 | — | — | WO | disclosed |
| US-20060128692-A1 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC (US) | 2006-06-15 | — | — | US | disclosed |
| US-20060122123-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1663254-A2 | ANTI-INFLAMATORY PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| US-20060115815-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| CN-1780631-A | anticancer phosphonate analogs | GILEAD SCIENCES INC (US) | 2006-05-31 | — | — | CN | disclosed |
| CN-1780643-A | Antiviral phosphonate analogs | GILEAD SCIENCES INC (US) | 2006-05-31 | — | — | CN | disclosed |
| CN-1780630-A | Phosphonate compounds having immunomodulatory activity | GILEAD SCIENCES INC (US) | 2006-05-31 | — | — | CN | disclosed |
| EP-1656387-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006047661-A2 | PHOSPHONATE DERIVATIVES OF MYCOPHENOLIC ACID | GILEAD SCIENCES, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006047507-A2 | PHOSPHONATE SUBSTITUTED KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. | 2006-04-13 | — | — | US | disclosed |
| US-20060079492-A1 | Compositions and treatment methods | BIOVIE INC. | 2006-04-13 | — | — | US | disclosed |
| US-20060063749-A1 | Pharmaceutical compositions and treatment methods - 5 | BIOVIE INC. | 2006-03-23 | — | — | US | disclosed |
| EP-1628685-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2006-03-01 | — | — | EP | disclosed |
| CN-1243767-C | Immunomodulatory steroids, in particular hemihydrate of 16 alpha-bromoepiandrosterone | HOLLIS EDEN PHARMACEUTICALS (US) | 2006-03-01 | — | — | CN | disclosed |
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. | 2006-02-16 | — | — | US | disclosed |
| CN-1733707-A | Compounds and methods for synthesis and therapy | GILEAD SCIENCES INC (US) | 2006-02-15 | — | — | CN | disclosed |
| WO-2006015261-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1620109-A2 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1620445-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1617848-A2 | ANTI-CANCER PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050282732-A1 | Pharmaceutical compositions and treatment methods-7 | BIOVIE INC. | 2005-12-22 | — | — | US | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050261237-A1 | Nucleoside phosphonate analogs | GILEAD SCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050256095-A1 | Asthma and colitis treatment methods | BIOVIE INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050256078-A1 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050227947-A1 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. | 2005-10-13 | — | — | US | disclosed |
| US-20050215525-A1 | Anti-infective phosphonate analogs | GILEAD SCIENCES, INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | GILEAD SCIENCES, INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| EP-1575486-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050197320-A1 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. | 2005-09-08 | — | — | US | disclosed |
| US-6939854-B2 | Peptide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| CN-1656109-A | Non-nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES INC (US) | 2005-08-17 | — | — | CN | disclosed |
| US-20050176758-A1 | 2-(hydroxy or methoxymethoxy)-4-(carboxy or alkoxycarbonyl)-5-(fluoro or hydrogen)-7-oxabicyclo(4.1.0)hept-3-ene chemical intermediates to neuraminidase inhibitors | GILEAD SCIENCES, INC. | 2005-08-11 | — | — | US | disclosed |
| CN-1649885-A | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050159366-A1 | Pharmaceutical compositions and treatment methods - 8 | BIOVIE INC. | 2005-07-21 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050153990-A1 | Phosphonate substituted kinase inhibitors | GILEAD SCIENCES, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005063258-A1 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1539183-A1 | THERAPEUTIC TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005044308-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | GILEAD SCIENCES, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050101581-A1 | Therapeutic treatment methods 2 | BIOVIE INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005042475-A2 | CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS | SENTION, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005039552-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS AS PHOSPHONATE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | SENTION, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| US-20050075321-A1 | Neurological disorder treatment methods | BIOVIE INC. | 2005-04-07 | — | — | US | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2005012324-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-1501841-A2 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6846806-B2 | Peptide inhibitors of Hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-25 | — | — | US | disclosed |
| CN-1185223-C | Novel compounds, their synthesis and therapeutic use | GILEAD SCIENCES INC (US) | 2005-01-19 | — | — | CN | disclosed |
| US-20040242465-A1 | Nucleotide analogs | BISCHOFBERGER NORBERT W (US) | 2004-12-02 | — | — | US | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004096285-A2 | ANTI-INFECTIVE PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096286-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096818-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096234-A2 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096233-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096287-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096237-A2 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220114-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220161-A1 | Pharmaceutical compositions and treatment methods-6 | BIOVIE INC. | 2004-11-04 | — | — | US | disclosed |
| EP-1458868-A2 | GENES AND PROTEINS INVOLVED IN THE BIOSYNTHESIS OF LIPOPEPTIDES | Ecopia Biosciences Inc. (CA) | 2004-09-22 | — | — | EP | disclosed |
| US-6774212-B2 | FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | PRIESTLEY E SCOTT (DE) | 2004-07-29 | — | — | US | disclosed |
| US-20040138187-A1 | Therapeutic treatment methods | BIOVIE INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20040116359-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1422234-A2 | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040097406-A1 | Pharmaceutical compositions and treatment methods - 4 | BIOVIE INC. | 2004-05-20 | — | — | US | disclosed |
| US-20040053999-A1 | Novel compounds and methods for synthesis and therapy | BISCHOFBERGER NORBERT W (US) | 2004-03-18 | — | — | US | disclosed |
| WO-2004019953-A1 | THERAPEUTIC TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-20040043973-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-03-04 | — | — | US | disclosed |
| US-6699855-B2 | PYRROLOPYRAZINONES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-02 | — | — | US | disclosed |
| EP-1372664-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6667299-B1 | 16-alpha-bromo-3-beta-hydroxy-5-alpha-androstan-17-one hemihydrate; 16-alpha-bromoepiandrosterone; steroid; immune modulator | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2003-12-23 | — | — | US | disclosed |
| WO-2003090691-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091264-A2 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-20030198981-A1 | Genes and proteins involved in the biosynthesis of lipopeptides | ECOPIA BIOSCIENCES, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003060127-A2 | GENES AND PROTEINS INVOLVED IN THE BIOSYNTHESIS OF LIPOPEPTIDES | ECOPIA BIOSCIENCES INC. (CA) | 2003-07-24 | — | — | WO | disclosed |
| EP-1314041-A2 | SCREEN FOR GLUTAMATE REUPTAKE INHIBITORS, STIMULATORS, AND MODULATORS | Annovis, Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030083231-A1 | Blood cell deficiency treatment method | BIOVIE INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | disclosed |
| US-6524807-B2 | Interleukin-1 beta converting enzyme for use in treating fever, sleep, eating and hypotensive, inflammatory, autoimmune, arthritis, septic shock, inflammatory bowel disease, diabetes and psoraisis | BASF AKTIENGELLSCHAFT (DE) | 2003-02-25 | — | — | US | disclosed |
| US-20020188022-A1 | Methods for modulation, stimulation, and inhibition of glutamate reuptake | ANNOVIS. INC. | 2002-12-12 | — | — | US | disclosed |
| EP-1261611-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-11-28 | — | — | US | disclosed |
| US-20020164762-A1 | Modified interleukin-1beta converting enzyme with increased stability | BASF AKTIENGESELLSCHAFT | 2002-11-07 | — | — | US | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2002069977-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020115688-A1 | Screen for glutamate reuptake inhibitors, stimulators, and modulators | ANNOVIS, INC. | 2002-08-22 | — | — | US | disclosed |
| EP-1228083-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | Hollis-Eden Pharmaceuticals Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| CN-1355809-A | Immunomodulatory steroids, in particular hemihydrate of 16 alpha-bromoepiandrosterone | HOLLIS EDEN PHARMACEUTICALS (US) | 2002-06-26 | — | — | CN | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| CN-1347693-A | Novel compounds, their synthesis and therapeutic use | GILEAD SCIENCES INC (US) | 2002-05-08 | — | — | CN | disclosed |
| US-6376674-B1 | BACTERICIDES; VIRICIDES | GILEAD SCIENCES, INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2002018941-A2 | SCREEN FOR GLUTAMATE REUPTAKE INHIBITORS, STIMULATORS, AND MODULATORS | ANNOVIS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-1163256-A1 | HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | Hollis-Eden Pharmaceuticals Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-20010041794-A1 | Nucleotide analogs | GILEAD SCIENCES, INC. | 2001-11-15 | — | — | US | disclosed |
| US-6310093-B1 | ADMINISTERING, IN AMOUNT EFFECTIVE TO REDUCE DAMAGE TO NEURONAL CELLS, COMPOUND WHICH SELECTIVELY INHIBITS EXTRACELLULAR GLUTAMINASE RELATIVE TO GLUTAMINASE PRESENT IN INTACT CELLS AND IS IMPERMEABLE TO INTACT CELL MEMBRANES | ELAN PHARMACEUTICALS, INC. | 2001-10-30 | — | — | US | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6242240-B1 | NUCLEIC ACID WHICH CODES FOR MODIFIED P10 SUBUNIT OF ENZYME WHICH HAS ASPARTIC ACID AT POSITION 381 REPLACED WITH ANOTHER AMINO ACID CAPABLE OF FORMING A SALT BRIDGE WITH ARGININE AT POSITION 383; X-RAY CRYSTALLOGRAPHY; SCREENING OF MODULATORS | BASF AKTIENGELLSCHAFT (DE) | 2001-06-05 | — | — | US | disclosed |
| US-6225460-B1 | PHOSPHOAMIDATE OR ESTER BOND THAT IS HYDROLYZED IN VIVO TO YIELD A CORRESPONDING PHOSPHONATE NUCLEOTIDE ANALOG. | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | disclosed |
| US-6225341-B1 | FOR INHIBITING NEURAMINIDASE; FOR THERAPY AND PROPHYLAXIS OF VIRUS INFECTION | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | disclosed |
| WO-2001023405-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| CN-1272105-A | Compound containing six-membered rings, processes for their preparation, and their use as medicaments | GILEAD SCIENCES INC (US) | 2000-11-01 | — | — | CN | disclosed |
| WO-2000056757-A1 | IMMUNOMODULATORY STEROIDS, IN PARTICULAR THE HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
| EP-0759917-B1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES INC (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0976734-A2 | Selective inhibitors of viral or bacterial neuraminidase | GILEAD SCIENCES, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| CN-1238762-A | Piperidine compounds | GILEAD SCIENCES INC (US) | 1999-12-15 | — | — | CN | disclosed |
| US-5994377-A | NEURAMINIDASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5958973-A | Polyhydroxy benzoic acid derivatives and their use as neuraminidase inhibitors | GILEAD SCIENCES, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5952375-A | NEURAMINIDASE INHIBITOR FOR INHIBITION OF VIRUSES, IN PARTICULAR INFLUENZA VIRUSES; FDA ORANGE BOOK LISTED PATENT FOR OSELTAMIVIR PHOSPHATE | GILEAD SCIENCES, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| WO-1999009825-A1 | METHOD OF PREVENTING NEURONAL DEATH | ELAN PHARMACEUTICALS, INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| US-5869315-A | Modified interleukin-1β converting enzyme with increased stability | BASF AKTIENGESELLSCHAFT (DE) | 1999-02-09 | — | — | US | disclosed |
| US-5866601-A | ACID CYCLOHEXENE DERIVATIVES, NEURAMINIDASE INHIBITORS SUCH AS OSELTAMIVIR | GILEAD SCIENCES, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5798340-A | ANTITUMOR/ANTINEOPLASTIC ACTIITY, VIRICIDES; BROAD SPECTRUM MICROBIOCIDES; THIOPHOSPHONATES HYDROLYZABLE IN VIVO; ORAL ADMINISTRATION; BIOAVAILABILITY; NONTOXIC; POTENCY | GILEAD SCIENCES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| US-5767100-A | ADMINISTERING NUCLEOTIDE ANALOGUES TO TREAT HERPES VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5763483-A | NEURAMINIDASE INHIBITOR TREATING INFLUENZA VIRUS INFECTION; OSELTAMIVIR OR THE FREE ACID THEREOF; FDA ORANGE BOOK LISTED PATENT FOR OSELTAMIVIR PHOSPHATE | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5756486-A | CYCLIZED NUCLEOTIDE; VIRICIDE | GILEAD SCIENCES, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5750729-A | REACTING PROTECTED PYRAN DERIVATIVES TO FORM NUCLEOTIDES | GILEAD SCIENCES,INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5693771-A | REACTING PROTECTED PYRAN COMPOUND WITH PHOSPHITE AND HETEROCYCLIC BASE | GILEAD SCIENCES, INC. (US) | 1997-12-02 | — | — | US | disclosed |
| US-5659023-A | HETEROCYCLIC FURANOSYL OR PYRANOSYL PHOSPHONATE; IMMUNOGENS, OLIGONUCLEOTIDES, ANTIINFECTIVES, ANTIINFLAMMATORY AGENTS | GILEAD SCIENCES, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| US-5656745-A | AMIDATE LINKAGE; ANTITUMOR, ANTICARCINOGENIC AGENTS | GILEAD SCIENCES, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| CN-1147813-A | Novel compounds, their synthesis and therapeutic use | GILEAD SCIENCES INC (US) | 1997-04-16 | — | — | CN | disclosed |
| US-5591851-A | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1996026933-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1996-09-06 | — | — | WO | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0337731-B1 | Peptide antibiotics | LILLY CO ELI (US) | 1996-01-31 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| JP-H06273417-A | ANTIBODY FOR MEVALONIC ACID AND DETERMINATION METHOD OF MEVALONIC ACID USING THE ANTIBODY | ONO PHARMACEUT CO LTD | 1994-09-30 | — | — | JP | disclosed |
| US-4977083-A | Feeding alkanoic or alkenoic acids, esters, salts or alcohols to cultures of Streptomyces fradiae | ELI LILLY AND COMPANY (US) | 1990-12-11 | — | — | US | disclosed |
| EP-0010421-B1 | MIXTURE OF ANTIBIOTICS DESIGNATED BY A-21978, PROCESS FOR ITS PRODUCTION, THEIR PHARMACEUTICAL COMPOSITIONS AND PRODUCING MICROORGANISM | ELI LILLY AND COMPANY (US) | 1990-10-10 | — | — | EP | disclosed |
| EP-0337731-A2 | Peptide antibiotics | ELI LILLY AND COMPANY (US) | 1989-10-18 | — | — | EP | disclosed |
| US-4874878-A | CHEMICAL INTERMEDIATES FOR ANTIDEPRESSANTS | ADIR ET CIE (FR) | 1989-10-17 | — | — | US | disclosed |
| US-4851429-A | ANTIDEPRESSANT, TRANQUILIZERS | ADIR ET CIE (FR) | 1989-07-25 | — | — | US | disclosed |
| US-4696981-A | ANHYDROPOLYASPARTIC ACID (IMIDE) FROM AMMONIUM SALT OR AMIDE OF MALIC OR MALEIC ACID | DIAMOND SHAMROCK CHEMICALS COMPANY (US) | 1987-09-29 | — | — | US | disclosed |
| US-RE32455-E | A-21978 antibiotics and process for their production | ELI LILLY AND COMPANY (US) | 1987-07-07 | — | — | US | disclosed |
| US-RE32333-E | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1987-01-20 | — | — | US | disclosed |
| US-4590260-A | SUITABLE FOR INDUSTRIAL USE | FUSO CHEMICAL CO., LTD. (JP) | 1986-05-20 | — | — | US | disclosed |
| US-RE31396-E | A-21978 Antibiotics and process for their production | ELI LILLY AND COMPANY (US) | 1983-09-27 | — | — | US | disclosed |
| US-4331594-A | PEPTIDE ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1982-05-25 | — | — | US | disclosed |
| US-4208403-A | A-21978 Antibiotics and process for their production | ELI LILLY AND COMPANY (US) | 1980-06-17 | — | — | US | disclosed |
| EP-0010421-A1 | Mixture of antibiotics designated by A-21978, process for its production, their pharmaceutical compositions and producing microorganism | ELI LILLY AND COMPANY (US) | 1980-04-30 | — | — | EP | disclosed |
| US-3957760-A | AMINO ACID DERIVATIVES | E. R. SQUIBB & SONS, INC. (US) | 1976-05-18 | — | — | US | disclosed |
| US-3957760-A | AMINO ACID DERIVATIVES | E. R. SQUIBB & SONS, INC. (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275938-A1 | Therapeutic Treatment Methods | HSD3B1, HSD3B2, HSD17B1 | SLC7A5 4223/4885BHMT 1791/4885TDP1 3097/4885 |
| US-20040242465-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | SLC7A5 716/4885BHMT 1017/4885TDP1 290/4885 |
| US-20070275937-A1 | Therapeutic Treatment Methods | HSD3B1, HSD3B2, HSD17B1 | SLC7A5 4223/4885BHMT 1791/4885TDP1 3097/4885 |
| US-20060128692-A1 | Non nucleoside reverse transcriptase inhibitors | TYMP, PNP, ITPA | SLC7A5 2705/4885BHMT 825/4885TDP1 75/4885 |
| US-20090156558-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | TYMP, PHOSPHO1, PHPT1 | SLC7A5 581/4885BHMT 1540/4885TDP1 1113/4885 |
| US-20140228744-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | FABP6, ALPI, KRT18 | SLC7A5 3308/4885BHMT 1059/4885TDP1 3450/4885 |
| US-20090202470-A1 | Phosphonate Analogs of Hiv Inhibitor Compounds | PIK3CA, TYMP, ITPA | SLC7A5 1173/4885BHMT 1934/4885TDP1 1262/4885 |
| US-20020188022-A1 | Methods for modulation, stimulation, and inhibition of glutamate reuptake | SLC1A2, SLC18A2, SLC1A1 | SLC7A5 80/4885BHMT 519/4885TDP1 1911/4885 |
| US-20070049754-A1 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | INPP5D, INPPL1, MTAP | SLC7A5 3708/4885BHMT 2682/4885TDP1 331/4885 |
| US-20110098260-A1 | Steroid Compounds and Formulations | AR, NR5A1, CYP17A1 | SLC7A5 4857/4885BHMT 4276/4885TDP1 4036/4885 |
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | PHOSPHO1, NFATC1, IFNG | SLC7A5 4130/4885BHMT 828/4885TDP1 2777/4885 |
| US-20050153990-A1 | Phosphonate substituted kinase inhibitors | PIK3CA, PNKP, PIK3CB | SLC7A5 1398/4885BHMT 2513/4885TDP1 1272/4885 |
| US-20110009372-A1 | Compounds and compositions | HSD3B1, CYP17A1, HSD17B1 | SLC7A5 3441/4885BHMT 1234/4885TDP1 2648/4885 |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | SLC7A5 1394/4885BHMT 3289/4885TDP1 976/4885 |
| US-10377699-B2 | Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue | SCD, SCD5, FASN | SLC7A5 495/4885BHMT 3145/4885TDP1 4270/4885 |
| US-20080167270-A1 | ANTI-INFECTIVE PHOSPHONATE ANALOGS | PHOSPHO1, PGLS, PSPH | SLC7A5 1213/4885BHMT 4125/4885TDP1 2898/4885 |
| US-20170088576-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, ITPA | SLC7A5 1209/4885BHMT 3728/4885TDP1 1182/4885 |
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | TYMP, PNP, NUDT1 | SLC7A5 631/4885BHMT 1352/4885TDP1 340/4885 |
| US-20070072809-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | SLC7A5 2776/4885BHMT 3495/4885TDP1 3081/4885 |
| US-20080045490-A1 | Pharmaceutical Compositions | HSD3B1, HSD17B3, HSD17B1 | SLC7A5 4015/4885BHMT 1371/4885TDP1 2454/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | SLC7A5 1394/4885BHMT 3289/4885TDP1 976/4885 |
| US-20120315224-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | FABP6, ALPI, KRT18 | SLC7A5 3308/4885BHMT 1059/4885TDP1 3450/4885 |
| US-20030060425-A1 | Immune modulation method using steroid compounds | HSD3B1, NR5A1, HSD17B1 | SLC7A5 4125/4885BHMT 1283/4885TDP1 3466/4885 |
| US-20090215737-A1 | Pharmaceutical Compositions - 2 | HSD3B2, HSD3B1, HSD17B2 | SLC7A5 4612/4885BHMT 1702/4885TDP1 3304/4885 |
| US-20100240633-A1 | Cancer treatment methods | AR, KLK3, ACP3 | SLC7A5 4873/4885BHMT 2335/4885TDP1 2951/4885 |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | SLC7A5 3230/4885BHMT 919/4885TDP1 1526/4885 |
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | SLC7A5 975/4885BHMT 1785/4885TDP1 1264/4885 |
| US-10647746-B2 | Antibacterial cyclic lipopeptides | NRDC, NGLY1, LNPEP | SLC7A5 801/4885BHMT 3980/4885TDP1 4605/4885 |
| US-20010041794-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | SLC7A5 716/4885BHMT 1017/4885TDP1 290/4885 |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | SLC7A5 1394/4885BHMT 3289/4885TDP1 976/4885 |
| US-20080015174-A1 | Metabolic Disease Treatments | HSD3B1, HSD17B1, CYP27A1 | SLC7A5 4156/4885BHMT 1276/4885TDP1 3072/4885 |
| US-20120071454-A1 | Steroid Compounds and Treatment Methods | AR, NR5A1, CYP17A1 | SLC7A5 4878/4885BHMT 2484/4885TDP1 3706/4885 |
| US-20130059887-A1 | SUBSTITUTED PYRIDOXINE-LACTAM CARBOXYLATE SALTS | PLPBP, PNPO, ADH5 | SLC7A5 170/4885BHMT 1031/4885TDP1 2459/4885 |
| US-20030083231-A1 | Blood cell deficiency treatment method | THPO, HPGDS, MPL | SLC7A5 4767/4885BHMT 2766/4885TDP1 1236/4885 |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | PHOSPHO1, NFATC1, IFNG | SLC7A5 4130/4885BHMT 828/4885TDP1 2777/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | SLC7A5 975/4885BHMT 1785/4885TDP1 1264/4885 |
| US-20080107628-A1 | Polymerase inhibitors | POLR2H, POLR2E, POLR1E | SLC7A5 3785/4885BHMT 4549/4885TDP1 278/4885 |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | SLC7A5 1394/4885BHMT 3289/4885TDP1 976/4885 |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | SLC7A5 860/4885BHMT 2833/4885TDP1 3065/4885 |
| US-11572477-B2 | Prevention of biofilm formation | BPGM, GLO1, PGLS | SLC7A5 1760/4885BHMT 39/4885TDP1 2751/4885 |
| US-20050282732-A1 | Pharmaceutical compositions and treatment methods-7 | HSD17B7, IL17A, HSD3B1 | SLC7A5 3331/4885BHMT 2064/4885TDP1 3710/4885 |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | SLC7A5 975/4885BHMT 1785/4885TDP1 1264/4885 |
| US-20050215525-A1 | Anti-infective phosphonate analogs | PHOSPHO1, PGLS, PSPH | SLC7A5 1213/4885BHMT 4125/4885TDP1 2898/4885 |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | HSD3B1, HSD3B2, HSD17B1 | SLC7A5 3692/4885BHMT 1053/4885TDP1 3106/4885 |
| US-20050227947-A1 | Phosphonate analogs for treating metabolic diseases | PHOSPHO1, G6PC1, PC | SLC7A5 1125/4885BHMT 847/4885TDP1 2295/4885 |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HSD3B1, HSD3B2, HSD17B13 | SLC7A5 3911/4885BHMT 2296/4885TDP1 3373/4885 |
| US-20070203354-A1 | Chemical Compositions and Methods of Making Them | PARG, PCBP1, POLI | SLC7A5 2378/4885BHMT 1952/4885TDP1 1064/4885 |
| US-20070027116-A1 | Therapeutic phosphonate derivatives | PPP5C, PPP3CA, PPP4R3A | SLC7A5 2229/4885BHMT 2864/4885TDP1 2643/4885 |
| US-20110144177-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | ACHE, BCHE, CHAT | SLC7A5 1468/4885BHMT 117/4885TDP1 1097/4885 |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | MPL, THPO, HSD3B2 | SLC7A5 4871/4885BHMT 3341/4885TDP1 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.